3-azido-2-methylpyridine | 106576-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-azido-2-methylpyridine
• CAS: 106576-54-9
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: OLPPATZLLGFDSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  27.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-azido-2-methylpyridine 、 sodium methylate 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 1.0h， 生成 2-methoxy-3-methyl-3H-[1,4]diazepine
  参考文献：
  名称：

  Regio-selective diazepine formation from 3-azidopyridines: The first examples of monocyclic 2H-1,4-diazepines.

  摘要：

  在甲醇钠存在下，对 4 位没有取代基的 2-取代的 3-叠氮吡啶 (5) 进行光解，可得到新型 2H-1，4-二氮杂卓 (8)，而在类似条件下对 2-未取代的 (1) 和 2，4-二取代的 3-叠氮吡啶 (10) 进行照射，可得到 5H-1，3-二氮杂卓。

  DOI：

  10.1248/cpb.33.5603
• 作为产物：
  描述：

  3-氨基-2-甲基吡啶 在 sodium azide 作用下， 生成 3-azido-2-methylpyridine
  参考文献：
  名称：

  Regio-selective diazepine formation from 3-azidopyridines: The first examples of monocyclic 2H-1,4-diazepines.

  摘要：

  在甲醇钠存在下，对 4 位没有取代基的 2-取代的 3-叠氮吡啶 (5) 进行光解，可得到新型 2H-1，4-二氮杂卓 (8)，而在类似条件下对 2-未取代的 (1) 和 2，4-二取代的 3-叠氮吡啶 (10) 进行照射，可得到 5H-1，3-二氮杂卓。

  DOI：

  10.1248/cpb.33.5603

文献信息

• Sawanishi, Hiroyuki; Tajima, Kayoko; Tsuchiya, Takashi, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 10, p. 4101 - 4109
  作者：Sawanishi, Hiroyuki、Tajima, Kayoko、Tsuchiya, Takashi

  DOI：——

  日期：——
• SAWANISHI, HIROYUKI;TSUCHIYA, TAKASHI, CHEM. AND PHARM. BULL., 1985, 33, N 12, 5603-5605
  作者：SAWANISHI, HIROYUKI、TSUCHIYA, TAKASHI

  DOI：——

  日期：——
• Single-Molecule Phenotype Analysis
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20170247686A1

  公开（公告）日：2017-08-31

  Aspects of the present disclosure include methods of producing modified polypeptides and modified polypeptide-ribosome or polypeptide-mRNA complexes, and methods of screening polynucleotide and polypeptide libraries. The present disclosure also provides polypeptide libraries useful in screening for single molecule phenotypes. Also provided are kits useful for producing polypeptides capable of being modified using methods disclosed herein.
• PI3K/LYN-ACLY Signaling Inhibition
  申请人：Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center

  公开号：US20220218659A1

  公开（公告）日：2022-07-14

  The present disclosure is directed, in part, to pharmaceutical compositions comprising a Src protein tyrosine kinase inhibitor, an ATP citrate lyase (ACLY) inhibitor, and a PI3K inhibitor, and/or a Src and PIP 2 /PIP 3 inhibitor of binding to ACLY, and a pharmaceutically acceptable carrier, methods of identifying a compound as a potential therapeutic agent for treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway in a cell, and methods of treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway.
• [EN] PI3K/LYN-ACLY SIGNALING INHIBITION<br/>[FR] INHIBITION DE LA SIGNALISATION PI3K/LYN-ACLY
  申请人：INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER

  公开号：WO2020243063A1

  公开（公告）日：2020-12-03

  The present disclosure is directed, in part, to pharmaceutical compositions comprising a Src protein tyrosine kinase inhibitor, an ATP citrate lyase (ACLY) inhibitor, and a PI3K inhibitor, and/or a Src and PIP2/PIP3 inhibitor of binding to ACLY, and a pharmaceutically acceptable carrier, methods of identifying a compound as a potential therapeutic agent for treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway in a cell, and methods of treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway.